Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 2 versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 2 versus TRIOSTAT.
THYROLAR-2 vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyrolar-2 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing metabolic rate, oxygen consumption, and protein synthesis.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
1/2 to 1 tablet (30-60 mg liotrix) orally once daily, titrated every 2-4 weeks by 1/2 tablet increments based on clinical response and thyroid function tests.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
6-7 days (euthyroid); clinical context: steady-state reached in 4-6 weeks
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal: 40% (as glucuronide and sulfate conjugates); Fecal: 20% (unabsorbed); Biliary: minor (<5%)
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone